Compare Abbott Laboratories (ABT) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs YieldMax AMZN Option Income Strategy ETF — how do they compare? Abbott Laboratories trades at $111.24 (market cap $187.95B), while YieldMax AMZN Option Income Strategy ETF trades at $11.31. The key difference: Abbott Laboratories pays a 2.32% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABT | AMZY | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $15.75 |
52-Week Low | $82.57 | $9.98 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
AMZY trades at $11.29, down 2.84% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides weekly dividend distributions, with recent payouts ranging from $0.06 to $0.14, supporting high yield but raising sustainability concerns. Key support is at $11, with resistance at $12, as the RSI indicates potential overbought conditions near-term.
The outlook for AMZY hinges on its ability to maintain high dividend yields without eroding net asset value. Risks include NAV erosion from its synthetic option strategy and underperformance versus Amazon stock. Analyst sentiment is cautious due to structural drawbacks, making it suitable only for income-focused investors aware of the trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
